Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth

 SINGAPORE, Oct. 1, 2026 /PRNewswire/ -- Emerald Clinical Trials, a leading global clinical research organization anchored in Asia-Pacific, today announced the appointment of Michael Stibilj as Chief Executive Officer, effective 1 October 2026. The appointment marks the beginning of the company's next phase of growth. 

Michael Stibilj, Emerald Clinical Trials Michael brings over 30 years of global CRO industry experience. He joins Emerald Clinical after six years with Novotech where he was Chief Operating Officer; prior to that he was CEO at PPC Group for three years and spent 22 years …READ FULL ARTICLE